AAM council continues fight for biosimilar adoption

The Biosimilars Council—part of the USA’s Association for Accessible Medicine (AAM) representing companies developing off-patent medicines—has provided an update on its activities on the regulatory, legislative and educational fronts.

According to the update, the council worked with IQVIA earlier this year to show how pharmacy benefit manager (PBM) schemes to control biosimilar Humira (adalimumab) cost patients and employers $6 billion in potential savings last year. 

Last week, the council built on this work with a new report showing how leading PBMs continue to manipulate biosimilar competition to their own profit, and at the expense of patients. The report notes that major PBMs continue to prefer the high-priced brand despite biosimilar alternatives with discounts of more than 80%.